Exagen Inc Q1 2024 Earnings Call Transcript Highlights Strong Revenue Growth and Margin ...
XGN Stock | USD 4.19 0.22 5.54% |
About 54% of Exagen's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Exagen Inc suggests that some traders are interested. Exagen's investing sentiment overview a quick insight into current market opportunities from investing in Exagen Inc. Many technical investors use Exagen Inc stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Exagen |
Total Revenue 14.4 million in Q1 2024, up 28.4 percent from 11.2 million in Q1 2023.Adjusted EBITDA Negative 2 million in Q1 2024, improved from negative 6.2 mi
Read at gurufocus.com
Exagen Fundamental Analysis
We analyze Exagen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exagen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exagen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Exagen is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Exagen Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Exagen stock to make a market-neutral strategy. Peer analysis of Exagen could also be used in its relative valuation, which is a method of valuing Exagen by comparing valuation metrics with similar companies.
Peers
Exagen Related Equities
CSTL | Castle Biosciences | 3.70 | ||||
PMD | Psychemedics | 0.86 | ||||
SHC | Sotera Health | 0.61 | ||||
SERA | Sera Prognostics | 0.15 | ||||
BNR | Burning Rock | 1.95 | ||||
FONR | Fonar | 2.43 | ||||
DRIO | DarioHealth Corp | 2.53 | ||||
BDSX | Biodesix | 5.56 |
Check out Exagen Hype Analysis, Exagen Correlation and Exagen Performance. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.